Vator Securities advises Urb-it on 23 MSEK Directed Share Issue
Urb-it AB operates in the logistics sector and provides parcel delivery services. Customers can be found in a number of sectors, with a main focus on the e-commerce market. The business is operated through several subsidiaries in France and Great Britain.
The share issue was directed to a pre-committed circle of existing investors, including Fjärde AP-fonden, Handelsbanken Fonder and Skandia.Read More
Vator Securities advises InCoax Networks on 50 MSEK Rights Issue
InCoax specializes in the innovation of reusing existing in-building infrastructure for fiber access, providing Multi-Gigabit broadband to the world’s leading telecom and broadband service operators. InCoax has successfully established a partnership with Google Fiber and completed field tests and received an initial order from an American Tier-1 operator, clearly demonstrating the company’s potential.
Target markets include US and Europe, markets with growing fiber infrastructure, low household connectivity and high labour costs, implying a huge potential for InCoax’s cost-efficient Fiber Access Extension solutions.Read More
Vator Securities advises Precise Biometrics on 83 MSEK Directed & Rights Issue
Precise Biometrics AB is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics.
Precise operates through two product areas: Digital Identity, which enable identification for physical access through biometrics (e.g., fingerprints, heart rate, facial and iris recognition) and Algo Software systems which is a leading embedded software for fingerprint recognition meeting various needs in smartphones, smart-lock doorhandles, and various applications in cars.Read More
Vator Securities advises Rebelle on 315 MSEK M&A
Rebelle operates the European online marketplace Rebelle.com for selling and buying luxury second hand fashion items and accessories.
Rebelle is offering products from the world’s most sought-after fashion brands, such as Louis Vuitton, Chanel, Gucci, Hermès and Prada while increasing customers awareness of sustainability and circularity within the fashion industry.Read More
Vator Securities advises Movs Technology Group on 45 MSEK Private Placement
Movs Technology Group is today the market leader in electric mopeds, and the leading dealer of electric bikes in Sweden. The company has developed several market-leading brands in Sweden: Baotian, Vässla, Drax, Niu and Lifebike.
The Mobility-as-a-Service service MOVS is a subscription service for long-term rental of bikes, as well as light electric vehicles such as electric bikes and electric mopeds.Read More
Vator Securities acts as Joint Bookrunner on IRRAS 215 MSEK Rights Issue
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients.
IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies.Read More
Vator Securities advises ZignSec on 59 MSEK Rights Issue
ZignSec AB (publ) is a RegTech company, providing an integrated end-to-end KYC, KYB compliance platform, facilitating seamless customer onboarding and monitoring, so clients can confidently expand operations internationally while remaining compliant.
Currently ZignSec has more than 500 customers spread across a range of industries where identification is essential, with the greatest concentration in financial services and other regulated activities.Read More
Vator Securities advises Moberg Pharma on 121 MSEK Rights Issue
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis.
Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company’s goal is to receive its first market approval and launch MOB-015 in 2023.Read More